Featured

SITC 2022 – Posters will be presented in person at the Boston Convention & Exhibition Center on Thursday, November 10th, 2022

Strattmont Group2022-11-09T11:50:08-05:00

Society for the Immunotherapy of Cancer 2022 Annual Meeting, November 8 – 12, Boston, MA,...

Dr. Philip M. Arlen gives presentation on recent NEO-201 clinical development at Biomarkers & Immuno US, 4th Annual Advances in Immuno-Oncology USA Congress, San Diego, CA, October 4, 2022

Strattmont Group2022-10-12T10:30:45-04:00

Dr. Philip M. Arlen gives presentation “Preclinical/Clinical Development of a Neo-Epitope Targeted Monoclonal Antibody for...

Precision Biologics, Inc. and National Cancer Institute Collaborators Deliver Poster Presentation at the ASCO Annual Meeting June 5, 2022

Strattmont Group2022-06-03T11:11:01-04:00

Precision Biologics, Inc. and our collaborators at the NCI deliver a poster presentation at the...

Dr. Philip M. Arlen gives Immunotherapy Section Opening Keynote at Festival of Biologics, San Diego, March 9, 2022

Strattmont Group2022-03-09T10:48:47-05:00

Dr. Philip M. Arlen gives Immunotherapy Section Opening Keynote at Festival of Biologics 2022, San...

Dr. Philip M. Arlen gives scientific presentation at Biomarkers UK: In-Person, November 8, 2021, Manchester, UK

Strattmont Group2021-11-05T14:50:15-04:00

Dr. Philip M. Arlen gives scientific presentation at Biomarkers UK: In-Person, Day 1 – November...

Phase II Clinical Trial NEO-201 in Combination with Pembrolizumab Detailed Study Information

Strattmont Group2021-10-28T11:57:03-04:00

The Phase 2 Clinical Trial with a safety lead in, combining Precision Biologics monoclonal antibody...

Precision Biologics to Deliver two Oral Presentations on our Clinical and Scientific Programs at 6th Annual Neoantigen Based Therapies Summit, October 26-28th, Digital Event

Strattmont Group2021-10-28T15:47:15-04:00

Dr Massimo Fantini, Director of Research is Presenting the following Talk entitled : “Stability Tests...

Precision Biologics Commences Phase 2 Clinical Trial using NEO-201 and Pembrolizumab as a 2nd line Therapy in Patients with Solid Tumors

Strattmont Group2021-10-14T11:22:55-04:00

Precision Biologics announces that a Phase 2 Clinical Trial, combining NEO-201 with Pembrolizumab, is recruiting...

Dr. Philip M. Arlen gives scientific presentation at the 4th Annual Europe Neoantigen Summit 20th-22nd April 2021

Strattmont Group2021-04-21T08:30:59-04:00

Dr. Philip M. Arlen gives scientific presentation at the 4th Annual Europe Neoantigen summit, Clinical...

Dr. Philip M. Arlen gives scientific presentation at the Festival of Biologics, World Immunotherapy Congress, USA

Strattmont Group2021-03-26T10:04:55-04:00

Dr. Philip M. Arlen gives scientific presentation at the Festival of Biologics, World Immunotherapy Congress,...